Priveterra Acquisition said that following its planned business combination with AEON Biopharma the combined company will list on the New York Stock Exchange.
a special purpose acquisition company, currently trades on the Nasdaq.
The combined company is expected to begin trading on NYSE on or about July 24, under the ticker symbol AEON. The companies originally said the combined company was expected to list on the Nasdaq under the ticker symbol AEON.
Privately-held AEON Biopharma is focused on developing its proprietary botulinum toxin complex ABP-450, or prabotulinumtoxinA, for therapeutic indications, the company said.